{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics&page=13",
    "query": {
      "condition": "Pharmacokinetics",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 9445,
    "total_pages": 945,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:38:22.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03609827",
      "title": "Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Malignancies",
        "Nonmalignant Diseases",
        "Immunodeficiencies",
        "Hemoglobinopathies",
        "Genetic Inborn Errors of Metabolism",
        "Fanconi's Anemia",
        "Thalassemia",
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 25,
      "start_date": "2015-09-01",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-10-04",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03609827"
    },
    {
      "nct_id": "NCT05499260",
      "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "CB03-154",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Zhimeng Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 70,
      "start_date": "2022-05-02",
      "completion_date": "2023-03-02",
      "has_results": false,
      "last_update_posted_date": "2022-08-16",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05499260"
    },
    {
      "nct_id": "NCT01723020",
      "title": "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancy",
        "Advanced Solid Tumors",
        "Cancer",
        "Oncology",
        "Oncology Patients",
        "Tumors",
        "Glioblastoma",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AMG 232",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2012-12-27",
      "completion_date": "2017-09-25",
      "has_results": false,
      "last_update_posted_date": "2021-09-02",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723020"
    },
    {
      "nct_id": "NCT01299142",
      "title": "Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "FGI-101-1A6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Functional Genetics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2011-01",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2011-02-18",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01299142"
    },
    {
      "nct_id": "NCT01476124",
      "title": "Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Restless Legs Syndrome"
      ],
      "interventions": [
        {
          "name": "morphine Placebo",
          "type": "DRUG"
        },
        {
          "name": "GEn 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "GEn Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2011-08",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2013-07-16",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476124"
    },
    {
      "nct_id": "NCT05226923",
      "title": "Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "KSP-1007",
          "type": "DRUG"
        },
        {
          "name": "Placebo:0.9% sodium chloride",
          "type": "OTHER"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sumitovant Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 123,
      "start_date": "2022-01-12",
      "completion_date": "2022-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05226923"
    },
    {
      "nct_id": "NCT02715479",
      "title": "A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "BMS955176",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2016-04",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2017-01-19",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715479"
    },
    {
      "nct_id": "NCT03105479",
      "title": "Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clostridium Difficile Infection"
      ],
      "interventions": [
        {
          "name": "Cadazolid",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin capsule",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2017-04-14",
      "completion_date": "2018-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 5,
      "location_summary": "Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Syracuse",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03105479"
    },
    {
      "nct_id": "NCT04873869",
      "title": "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-31",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04873869"
    },
    {
      "nct_id": "NCT06619054",
      "title": "A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adults",
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "KP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaken Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2024-10-24",
      "completion_date": "2025-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-10-22T10:38:22.413Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619054"
    }
  ]
}